5-amino-1mq nnmt inhibitor study obesity Among participants 4 to 66 years of age with acquired hypothalamic obesity, setmelanotide, a melanocortin-4 receptor agonist, led to significantly greater reductions in body-mass index and hunger than placebo at 52 weeks 5-amino-1mq Research Specifications & Lot #:Lot #: N95A1MQ10/0428 5-AMINO-1MQ Vial

5-amino-1mq nnmt inhibitor study obesity Among participants 4 to 66 years of age with acquired hypothalamic obesity, setmelanotide, a melanocortin-4 receptor agonist, led to significantly greater reductions in body-mass index and hunger than placebo at 52 weeks 5-amino-1mq Research Specifications & Lot #:Lot #: N95A1MQ10/0428 5-AMINO-1MQ Vial

5-amino-1mq Research Specifications & COA

Prepared vials should remain refrigerated between 2-8°C and protected from repeated temperature changes

5-AMINO-1MQ Vial

Lot #:Lot #: N95A1MQ10/0428

Notably, the weight loss was not driven by appetite suppression, distinguishing 5-Amino-1MQ from GLP-1 agonists and other appetite-modulating compounds